Willemsen Ruben H, van Dijk Marije, de Rijke Yolanda B, van Toorenenbergen Albert W, Mulder Paul G, Hokken-Koelega Anita C
Department of Pediatrics, Erasmus Medical Center Sophia, Room SP-3435, Dr. Molenwaterplein 60, 3015 GJ Rotterdam, The Netherlands.
J Clin Endocrinol Metab. 2007 Jan;92(1):117-23. doi: 10.1210/jc.2006-0852. Epub 2006 Sep 26.
Adiponectin and resistin are fat cell-derived hormones, which are thought to be respectively protective and disadvantageous with regard to the development of cardiovascular disease and diabetes mellitus type 2. Low birth weight has been associated with increased risks for the development of these diseases. In short, small-for-gestational-age (SGA) children, GH therapy has several positive effects regarding cardiovascular risk factors. On the other hand, concern has been expressed about the effects of GH therapy on insulin sensitivity.
We measured adiponectin and resistin levels in 136 short prepubertal children born SGA and their association with cardiovascular risk parameters and growth factors. Also, we compared the levels with normal-statured controls. The effect of GH treatment was evaluated in 50 short SGA children vs. baseline and vs. an untreated sex- and age-matched SGA control group.
Short SGA children had similar adiponectin and lower resistin levels, compared with normal-statured controls. In GH-treated SGA children, neither adiponectin nor resistin levels changed significantly during 2 yr of GH treatment. Compared with untreated sex- and age-matched SGA controls, GH-treated SGA children had similar adiponectin and lower resistin levels. Adiponectin correlated inversely with age but not any cardiovascular risk parameter or growth factor. Higher IGF-I levels in GH-treated children were associated with lower resistin levels.
Compared with normal-statured controls, short prepubertal SGA children had similar adiponectin and lower resistin levels. Two years of GH treatment had no effect on their adiponectin and resistin levels.
脂联素和抵抗素是脂肪细胞衍生的激素，被认为分别对心血管疾病和2型糖尿病的发展具有保护作用和不利影响。低出生体重与这些疾病发展风险增加有关。简而言之，对于小于胎龄（SGA）儿童，生长激素（GH）治疗在心血管危险因素方面有若干积极作用。另一方面，有人对GH治疗对胰岛素敏感性的影响表示担忧。
我们测量了136名青春期前出生时为SGA的矮小儿童的脂联素和抵抗素水平，以及它们与心血管风险参数和生长因子的关联。此外，我们将这些水平与正常身高的对照组进行了比较。在50名矮小的SGA儿童中评估了GH治疗的效果，与基线相比，并与未治疗的性别和年龄匹配的SGA对照组进行比较。
与正常身高的对照组相比，矮小的SGA儿童脂联素水平相似，抵抗素水平较低。在接受GH治疗的SGA儿童中，在2年的GH治疗期间，脂联素和抵抗素水平均未发生显著变化。与未治疗的性别和年龄匹配的SGA对照组相比，接受GH治疗的SGA儿童脂联素水平相似，抵抗素水平较低。脂联素与年龄呈负相关，但与任何心血管风险参数或生长因子均无相关性。接受GH治疗的儿童中较高的胰岛素样生长因子-I（IGF-I）水平与较低的抵抗素水平相关。
与正常身高的对照组相比，青春期前矮小的SGA儿童脂联素水平相似，抵抗素水平较低。两年的GH治疗对他们的脂联素和抵抗素水平没有影响。
